ID   SYAC_HUMAN              Reviewed;         968 AA.
AC   P49588; A6NF14; B4DR45; Q53GV7; Q96FA0;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=Alanine--tRNA ligase, cytoplasmic {ECO:0000255|HAMAP-Rule:MF_03133};
DE            EC=6.1.1.7 {ECO:0000255|HAMAP-Rule:MF_03133, ECO:0000269|PubMed:25817015};
DE   AltName: Full=Alanyl-tRNA synthetase {ECO:0000255|HAMAP-Rule:MF_03133};
DE            Short=AlaRS {ECO:0000255|HAMAP-Rule:MF_03133};
DE   AltName: Full=Renal carcinoma antigen NY-REN-42;
GN   Name=AARS {ECO:0000255|HAMAP-Rule:MF_03133};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7654687; DOI=10.1021/bi00033a004;
RA   Shiba K., Ripmaster T.L., Suzuki N., Nichols R., Plotz P., Noda T.,
RA   Schimmel P.;
RT   "Human alanyl-tRNA synthetase: conservation in evolution of catalytic
RT   core and microhelix recognition.";
RL   Biochemistry 34:10340-10349(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-11; 304-320 AND 684-695, ACETYLATION AT MET-1,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Osteosarcoma;
RA   Bienvenut W.V., Glen H., Brunton V.G., Frame M.C.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [8]
RP   IDENTIFICATION AS A RENAL CANCER ANTIGEN.
RC   TISSUE=Renal cell carcinoma;
RX   PubMed=10508479;
RX   DOI=10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5;
RA   Scanlan M.J., Gordan J.D., Williamson B., Stockert E., Bander N.H.,
RA   Jongeneel C.V., Gure A.O., Jaeger D., Jaeger E., Knuth A., Chen Y.-T.,
RA   Old L.J.;
RT   "Antigens recognized by autologous antibody in patients with renal-
RT   cell carcinoma.";
RL   Int. J. Cancer 83:456-464(1999).
RN   [9]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-555, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   DOMAIN EXCHANGE EXPERIMENTS.
RX   PubMed=19661429; DOI=10.1126/science.1174343;
RA   Guo M., Chong Y.E., Beebe K., Shapiro R., Yang X.-L., Schimmel P.;
RT   "The C-Ala domain brings together editing and aminoacylation functions
RT   on one tRNA.";
RL   Science 325:744-747(2009).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-19 AND LYS-876, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-399, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3; SER-8 AND SER-555,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   BIOPHYSICOCHEMICAL PROPERTIES, INVOLVEMENT IN EIEE29, VARIANTS EIEE29
RP   THR-81 AND GLY-751, CHARACTERIZATION OF VARIANTS EIEE29 THR-81 AND
RP   GLY-751, AND CATALYTIC ACTIVITY.
RX   PubMed=25817015; DOI=10.1016/j.ajhg.2015.02.012;
RA   Simons C., Griffin L.B., Helman G., Golas G., Pizzino A., Bloom M.,
RA   Murphy J.L., Crawford J., Evans S.H., Topper S., Whitehead M.T.,
RA   Schreiber J.M., Chapman K.A., Tifft C., Lu K.B., Gamper H.,
RA   Shigematsu M., Taft R.J., Antonellis A., Hou Y.M., Vanderver A.;
RT   "Loss-of-function alanyl-tRNA synthetase mutations cause an autosomal-
RT   recessive early-onset epileptic encephalopathy with persistent
RT   myelination defect.";
RL   Am. J. Hum. Genet. 96:675-681(2015).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   VARIANT CMT2N HIS-329.
RX   PubMed=20045102; DOI=10.1016/j.ajhg.2009.12.005;
RA   Latour P., Thauvin-Robinet C., Baudelet-Mery C., Soichot P., Cusin V.,
RA   Faivre L., Locatelli M.C., Mayencon M., Sarcey A., Broussolle E.,
RA   Camu W., David A., Rousson R.;
RT   "A major determinant for binding and aminoacylation of tRNA(Ala) in
RT   cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal
RT   Charcot-Marie-Tooth disease.";
RL   Am. J. Hum. Genet. 86:77-82(2010).
RN   [23]
RP   VARIANT CMT2N TYR-71.
RX   PubMed=22206013; DOI=10.1371/journal.pone.0029393;
RA   Lin K.P., Soong B.W., Yang C.C., Huang L.W., Chang M.H., Lee I.H.,
RA   Antonellis A., Lee Y.C.;
RT   "The mutational spectrum in a cohort of Charcot-Marie-Tooth disease
RT   type 2 among the Han Chinese in Taiwan.";
RL   PLoS ONE 6:E29393-E29393(2011).
RN   [24]
RP   VARIANT CMT2N HIS-329, AND CHARACTERIZATION OF VARIANT CMT2N HIS-329.
RX   PubMed=22009580; DOI=10.1002/humu.21635;
RA   McLaughlin H.M., Sakaguchi R., Giblin W., Wilson T.E., Biesecker L.,
RA   Lupski J.R., Talbot K., Vance J.M., Zuchner S., Lee Y.C.,
RA   Kennerson M., Hou Y.M., Nicholson G., Antonellis A.;
RT   "A recurrent loss-of-function alanyl-tRNA synthetase (AARS) mutation
RT   in patients with Charcot-Marie-Tooth disease type 2N (CMT2N).";
RL   Hum. Mutat. 33:244-253(2012).
RN   [25]
RP   VARIANT MET-608.
RX   PubMed=24627108; DOI=10.1007/s00415-014-7289-8;
RA   Schabhuettl M., Wieland T., Senderek J., Baets J., Timmerman V.,
RA   De Jonghe P., Reilly M.M., Stieglbauer K., Laich E., Windhager R.,
RA   Erwa W., Trajanoski S., Strom T.M., Auer-Grumbach M.;
RT   "Whole-exome sequencing in patients with inherited neuropathies:
RT   outcome and challenges.";
RL   J. Neurol. 261:970-982(2014).
CC   -!- FUNCTION: Catalyzes the attachment of alanine to tRNA(Ala) in a
CC       two-step reaction: alanine is first activated by ATP to form Ala-
CC       AMP and then transferred to the acceptor end of tRNA(Ala). Also
CC       edits incorrectly charged tRNA(Ala) via its editing domain.
CC       {ECO:0000255|HAMAP-Rule:MF_03133}.
CC   -!- CATALYTIC ACTIVITY: ATP + L-alanine + tRNA(Ala) = AMP +
CC       diphosphate + L-alanyl-tRNA(Ala). {ECO:0000255|HAMAP-
CC       Rule:MF_03133, ECO:0000269|PubMed:25817015}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_03133};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000255|HAMAP-
CC       Rule:MF_03133};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=3.1 uM for tRNA(Ala) (at 37 Celsius)
CC         {ECO:0000269|PubMed:25817015};
CC         Note=kcat is 0.4 sec(-1). {ECO:0000269|PubMed:25817015};
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03133}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49588-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P49588-2; Sequence=VSP_057201, VSP_057202;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: Consists of three domains; the N-terminal catalytic
CC       domain, the editing domain and the C-terminal C-Ala domain. The
CC       editing domain removes incorrectly charged amino acids, while the
CC       C-Ala domain, along with tRNA(Ala), serves as a bridge to
CC       cooperatively bring together the editing and aminoacylation
CC       centers thus stimulating deacylation of misacylated tRNAs.
CC       {ECO:0000255|HAMAP-Rule:MF_03133}.
CC   -!- DOMAIN: The C-terminal C-Ala domain (residues 756 to 968), along
CC       with tRNA(Ala), serves as a bridge to cooperatively bring together
CC       the editing and aminoacylation centers thus stimulating
CC       deacylation of misacylated tRNAs. The human domain can be used in
CC       vitro to replace the corresponding domain in E.coli.
CC       {ECO:0000269|PubMed:19661429}.
CC   -!- PTM: ISGylated. {ECO:0000255|HAMAP-Rule:MF_03133,
CC       ECO:0000269|PubMed:16139798}.
CC   -!- DISEASE: Charcot-Marie-Tooth disease 2N (CMT2N) [MIM:613287]: An
CC       axonal form of Charcot-Marie-Tooth disease, a disorder of the
CC       peripheral nervous system, characterized by progressive weakness
CC       and atrophy, initially of the peroneal muscles and later of the
CC       distal muscles of the arms. Charcot-Marie-Tooth disease is
CC       classified in two main groups on the basis of electrophysiologic
CC       properties and histopathology: primary peripheral demyelinating
CC       neuropathies (designated CMT1 when they are dominantly inherited)
CC       and primary peripheral axonal neuropathies (CMT2). Neuropathies of
CC       the CMT2 group are characterized by signs of axonal degeneration
CC       in the absence of obvious myelin alterations, normal or slightly
CC       reduced nerve conduction velocities, and progressive distal muscle
CC       weakness and atrophy. Nerve conduction velocities are normal or
CC       slightly reduced. {ECO:0000269|PubMed:20045102,
CC       ECO:0000269|PubMed:22009580, ECO:0000269|PubMed:22206013}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 29 (EIEE29)
CC       [MIM:616339]: A form of epileptic encephalopathy, a heterogeneous
CC       group of severe childhood onset epilepsies characterized by
CC       refractory seizures, neurodevelopmental impairment, and poor
CC       prognosis. Development is normal prior to seizure onset, after
CC       which cognitive and motor delays become apparent. EIEE29 patients
CC       manifest severe infantile epileptic encephalopathy, clubfoot,
CC       absent deep tendon reflexes, extrapyramidal symptoms, and
CC       persistently deficient myelination. {ECO:0000269|PubMed:25817015}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the class-II aminoacyl-tRNA synthetase
CC       family. {ECO:0000255|HAMAP-Rule:MF_03133}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D32050; BAA06808.1; -; mRNA.
DR   EMBL; AK299098; BAG61157.1; -; mRNA.
DR   EMBL; AK222824; BAD96544.1; -; mRNA.
DR   EMBL; AC012184; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471241; EAW51839.1; -; Genomic_DNA.
DR   EMBL; BC011451; AAH11451.1; -; mRNA.
DR   CCDS; CCDS32474.1; -. [P49588-1]
DR   PIR; I60107; I60107.
DR   RefSeq; NP_001596.2; NM_001605.2. [P49588-1]
DR   UniGene; Hs.315137; -.
DR   PDB; 4XEM; X-ray; 1.28 A; A=1-455.
DR   PDB; 4XEO; X-ray; 1.38 A; A/B=1-455.
DR   PDB; 5KNN; X-ray; 2.68 A; A/B/C/D/E/F/G/H=4-453.
DR   PDB; 5T5S; X-ray; 2.20 A; A=757-965.
DR   PDB; 5T76; X-ray; 2.00 A; A=757-965.
DR   PDBsum; 4XEM; -.
DR   PDBsum; 4XEO; -.
DR   PDBsum; 5KNN; -.
DR   PDBsum; 5T5S; -.
DR   PDBsum; 5T76; -.
DR   ProteinModelPortal; P49588; -.
DR   SMR; P49588; -.
DR   BioGrid; 106534; 52.
DR   IntAct; P49588; 6.
DR   MINT; MINT-1490092; -.
DR   STRING; 9606.ENSP00000261772; -.
DR   BindingDB; P49588; -.
DR   ChEMBL; CHEMBL3574; -.
DR   DrugBank; DB00160; L-Alanine.
DR   iPTMnet; P49588; -.
DR   PhosphoSitePlus; P49588; -.
DR   SwissPalm; P49588; -.
DR   BioMuta; AARS; -.
DR   DMDM; 115502460; -.
DR   EPD; P49588; -.
DR   MaxQB; P49588; -.
DR   PaxDb; P49588; -.
DR   PeptideAtlas; P49588; -.
DR   PRIDE; P49588; -.
DR   DNASU; 16; -.
DR   Ensembl; ENST00000261772; ENSP00000261772; ENSG00000090861. [P49588-1]
DR   GeneID; 16; -.
DR   KEGG; hsa:16; -.
DR   UCSC; uc002eyn.2; human. [P49588-1]
DR   CTD; 16; -.
DR   DisGeNET; 16; -.
DR   GeneCards; AARS; -.
DR   GeneReviews; AARS; -.
DR   HGNC; HGNC:20; AARS.
DR   HPA; CAB034261; -.
DR   HPA; HPA040870; -.
DR   HPA; HPA044223; -.
DR   MalaCards; AARS; -.
DR   MIM; 601065; gene.
DR   MIM; 613287; phenotype.
DR   MIM; 616339; phenotype.
DR   neXtProt; NX_P49588; -.
DR   OpenTargets; ENSG00000090861; -.
DR   Orphanet; 228174; Autosomal dominant Charcot-Marie-Tooth disease type 2N.
DR   PharmGKB; PA24367; -.
DR   eggNOG; KOG0188; Eukaryota.
DR   eggNOG; COG0013; LUCA.
DR   GeneTree; ENSGT00390000016019; -.
DR   HOGENOM; HOG000156964; -.
DR   HOVERGEN; HBG017874; -.
DR   InParanoid; P49588; -.
DR   KO; K01872; -.
DR   OMA; FDRIKKM; -.
DR   OrthoDB; EOG091G00Z9; -.
DR   PhylomeDB; P49588; -.
DR   TreeFam; TF300737; -.
DR   Reactome; R-HSA-379716; Cytosolic tRNA aminoacylation.
DR   ChiTaRS; AARS; human.
DR   GenomeRNAi; 16; -.
DR   PRO; PR:P49588; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000090861; -.
DR   CleanEx; HS_AARS; -.
DR   ExpressionAtlas; P49588; baseline and differential.
DR   Genevisible; P49588; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004813; F:alanine-tRNA ligase activity; IBA:GO_Central.
DR   GO; GO:0016597; F:amino acid binding; IBA:GO_Central.
DR   GO; GO:0002161; F:aminoacyl-tRNA editing activity; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000049; F:tRNA binding; IBA:GO_Central.
DR   GO; GO:0006419; P:alanyl-tRNA aminoacylation; IBA:GO_Central.
DR   GO; GO:0021680; P:cerebellar Purkinje cell layer development; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IEA:Ensembl.
DR   GO; GO:0006418; P:tRNA aminoacylation for protein translation; TAS:Reactome.
DR   GO; GO:0006400; P:tRNA modification; IBA:GO_Central.
DR   GO; GO:0008033; P:tRNA processing; TAS:ProtInc.
DR   HAMAP; MF_00036_B; Ala_tRNA_synth_B; 1.
DR   InterPro; IPR002318; Ala-tRNA-lgiase_IIc.
DR   InterPro; IPR018162; Ala-tRNA-ligase_IIc_anticod-bd.
DR   InterPro; IPR018165; Ala-tRNA-synth_IIc_core.
DR   InterPro; IPR018164; Ala-tRNA-synth_IIc_N.
DR   InterPro; IPR023033; Ala_tRNA_ligase_euk/bac.
DR   InterPro; IPR003156; DHHA1_dom.
DR   InterPro; IPR018163; Thr/Ala-tRNA-synth_IIc_edit.
DR   InterPro; IPR009000; Transl_B-barrel.
DR   InterPro; IPR012947; tRNA_SAD.
DR   Pfam; PF02272; DHHA1; 1.
DR   Pfam; PF01411; tRNA-synt_2c; 1.
DR   Pfam; PF07973; tRNA_SAD; 1.
DR   PRINTS; PR00980; TRNASYNTHALA.
DR   SMART; SM00863; tRNA_SAD; 1.
DR   SUPFAM; SSF101353; SSF101353; 1.
DR   SUPFAM; SSF50447; SSF50447; 1.
DR   SUPFAM; SSF55186; SSF55186; 1.
DR   TIGRFAMs; TIGR00344; alaS; 1.
DR   PROSITE; PS50860; AA_TRNA_LIGASE_II_ALA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Aminoacyl-tRNA synthetase; ATP-binding; Charcot-Marie-Tooth disease;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Epilepsy; Ligase; Metal-binding; Neurodegeneration;
KW   Neuropathy; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Protein biosynthesis; Reference proteome; RNA-binding; tRNA-binding;
KW   Ubl conjugation; Zinc.
FT   CHAIN         1    968       Alanine--tRNA ligase, cytoplasmic.
FT                                /FTId=PRO_0000075281.
FT   METAL       605    605       Zinc. {ECO:0000255|HAMAP-Rule:MF_03133}.
FT   METAL       609    609       Zinc. {ECO:0000255|HAMAP-Rule:MF_03133}.
FT   METAL       723    723       Zinc. {ECO:0000255|HAMAP-Rule:MF_03133}.
FT   METAL       727    727       Zinc. {ECO:0000255|HAMAP-Rule:MF_03133}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000255|HAMAP-Rule:MF_03133,
FT                                ECO:0000269|Ref.7}.
FT   MOD_RES       3      3       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES       8      8       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      19     19       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     399    399       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     555    555       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     876    876       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ     160    160       G -> GTYLYSFVR (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057201.
FT   VAR_SEQ     869    869       K -> KATQGPGSPPLGLISSL (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_057202.
FT   VARIANT      71     71       N -> Y (in CMT2N; dbSNP:rs387906792).
FT                                {ECO:0000269|PubMed:22206013}.
FT                                /FTId=VAR_067084.
FT   VARIANT      81     81       K -> T (in EIEE29; hypomorphic allele;
FT                                results in only 2-fold reduction in
FT                                aminoacylation efficiency;
FT                                dbSNP:rs786205157).
FT                                {ECO:0000269|PubMed:25817015}.
FT                                /FTId=VAR_073719.
FT   VARIANT     275    275       G -> D (in dbSNP:rs11537667).
FT                                /FTId=VAR_028204.
FT   VARIANT     329    329       R -> H (in CMT2N; severely reduces enzyme
FT                                activity; dbSNP:rs267606621).
FT                                {ECO:0000269|PubMed:20045102,
FT                                ECO:0000269|PubMed:22009580}.
FT                                /FTId=VAR_063527.
FT   VARIANT     608    608       T -> M (found in a patient with distal
FT                                hereditary motor neuropathy; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:24627108}.
FT                                /FTId=VAR_073293.
FT   VARIANT     751    751       R -> G (in EIEE29; results in 10-fold
FT                                reduction in aminoacylation efficiency;
FT                                dbSNP:rs143370729).
FT                                {ECO:0000269|PubMed:25817015}.
FT                                /FTId=VAR_073720.
FT   CONFLICT     82     82       H -> Q (in Ref. 1; BAA06808).
FT                                {ECO:0000305}.
FT   CONFLICT    334    334       Y -> C (in Ref. 2; BAG61157).
FT                                {ECO:0000305}.
FT   CONFLICT    763    763       A -> T (in Ref. 2; BAG61157).
FT                                {ECO:0000305}.
FT   CONFLICT    867    867       S -> T (in Ref. 3; BAD96544).
FT                                {ECO:0000305}.
FT   HELIX         7     20       {ECO:0000244|PDB:4XEM}.
FT   STRAND       34     36       {ECO:0000244|PDB:5KNN}.
FT   HELIX        45     49       {ECO:0000244|PDB:4XEM}.
FT   HELIX        50     53       {ECO:0000244|PDB:4XEM}.
FT   HELIX        62     65       {ECO:0000244|PDB:4XEM}.
FT   STRAND       68     76       {ECO:0000244|PDB:4XEM}.
FT   STRAND       78     81       {ECO:0000244|PDB:4XEO}.
FT   HELIX        85     87       {ECO:0000244|PDB:4XEM}.
FT   STRAND       90     93       {ECO:0000244|PDB:4XEM}.
FT   STRAND       96    109       {ECO:0000244|PDB:4XEM}.
FT   HELIX       111    123       {ECO:0000244|PDB:4XEM}.
FT   HELIX       130    132       {ECO:0000244|PDB:4XEM}.
FT   STRAND      133    138       {ECO:0000244|PDB:4XEM}.
FT   HELIX       142    144       {ECO:0000244|PDB:4XEM}.
FT   HELIX       150    158       {ECO:0000244|PDB:4XEM}.
FT   HELIX       163    165       {ECO:0000244|PDB:4XEM}.
FT   STRAND      166    169       {ECO:0000244|PDB:4XEM}.
FT   HELIX       171    174       {ECO:0000244|PDB:4XEM}.
FT   STRAND      178    195       {ECO:0000244|PDB:4XEM}.
FT   HELIX       201    203       {ECO:0000244|PDB:4XEM}.
FT   TURN        204    207       {ECO:0000244|PDB:4XEM}.
FT   STRAND      211    224       {ECO:0000244|PDB:4XEM}.
FT   STRAND      230    243       {ECO:0000244|PDB:4XEM}.
FT   HELIX       244    251       {ECO:0000244|PDB:4XEM}.
FT   HELIX       257    259       {ECO:0000244|PDB:4XEM}.
FT   TURN        261    263       {ECO:0000244|PDB:4XEM}.
FT   HELIX       264    274       {ECO:0000244|PDB:4XEM}.
FT   HELIX       284    286       {ECO:0000244|PDB:4XEM}.
FT   HELIX       291    310       {ECO:0000244|PDB:4XEM}.
FT   HELIX       319    339       {ECO:0000244|PDB:4XEM}.
FT   TURN        343    345       {ECO:0000244|PDB:4XEM}.
FT   HELIX       346    349       {ECO:0000244|PDB:4XEM}.
FT   HELIX       350    357       {ECO:0000244|PDB:4XEM}.
FT   TURN        358    360       {ECO:0000244|PDB:4XEM}.
FT   HELIX       362    365       {ECO:0000244|PDB:4XEM}.
FT   HELIX       368    383       {ECO:0000244|PDB:4XEM}.
FT   HELIX       386    399       {ECO:0000244|PDB:5KNN}.
FT   TURN        400    402       {ECO:0000244|PDB:5KNN}.
FT   HELIX       408    416       {ECO:0000244|PDB:5KNN}.
FT   HELIX       422    431       {ECO:0000244|PDB:5KNN}.
FT   HELIX       438    450       {ECO:0000244|PDB:5KNN}.
FT   HELIX       759    782       {ECO:0000244|PDB:5T76}.
FT   HELIX       789    804       {ECO:0000244|PDB:5T76}.
FT   HELIX       809    851       {ECO:0000244|PDB:5T76}.
FT   STRAND      856    861       {ECO:0000244|PDB:5T76}.
FT   HELIX       868    881       {ECO:0000244|PDB:5T76}.
FT   STRAND      886    893       {ECO:0000244|PDB:5T76}.
FT   TURN        894    897       {ECO:0000244|PDB:5T76}.
FT   STRAND      898    904       {ECO:0000244|PDB:5T76}.
FT   HELIX       907    912       {ECO:0000244|PDB:5T76}.
FT   HELIX       916    924       {ECO:0000244|PDB:5T76}.
FT   TURN        925    928       {ECO:0000244|PDB:5T76}.
FT   STRAND      929    933       {ECO:0000244|PDB:5T76}.
FT   STRAND      935    943       {ECO:0000244|PDB:5T76}.
FT   HELIX       945    947       {ECO:0000244|PDB:5T76}.
FT   HELIX       948    960       {ECO:0000244|PDB:5T76}.
SQ   SEQUENCE   968 AA;  106810 MW;  8683F111CEE42506 CRC64;
     MDSTLTASEI RQRFIDFFKR NEHTYVHSSA TIPLDDPTLL FANAGMNQFK PIFLNTIDPS
     HPMAKLSRAA NTQKCIRAGG KHNDLDDVGK DVYHHTFFEM LGSWSFGDYF KELACKMALE
     LLTQEFGIPI ERLYVTYFGG DEAAGLEADL ECKQIWQNLG LDDTKILPGN MKDNFWEMGD
     TGPCGPCSEI HYDRIGGRDA AHLVNQDDPN VLEIWNLVFI QYNREADGIL KPLPKKSIDT
     GMGLERLVSV LQNKMSNYDT DLFVPYFEAI QKGTGARPYT GKVGAEDADG IDMAYRVLAD
     HARTITVALA DGGRPDNTGR GYVLRRILRR AVRYAHEKLN ASRGFFATLV DVVVQSLGDA
     FPELKKDPDM VKDIINEEEV QFLKTLSRGR RILDRKIQSL GDSKTIPGDT AWLLYDTYGF
     PVDLTGLIAE EKGLVVDMDG FEEERKLAQL KSQGKGAGGE DLIMLDIYAI EELRARGLEV
     TDDSPKYNYH LDSSGSYVFE NTVATVMALR REKMFVEEVS TGQECGVVLD KTCFYAEQGG
     QIYDEGYLVK VDDSSEDKTE FTVKNAQVRG GYVLHIGTIY GDLKVGDQVW LFIDEPRRRP
     IMSNHTATHI LNFALRSVLG EADQKGSLVA PDRLRFDFTA KGAMSTQQIK KAEEIANEMI
     EAAKAVYTQD CPLAAAKAIQ GLRAVFDETY PDPVRVVSIG VPVSELLDDP SGPAGSLTSV
     EFCGGTHLRN SSHAGAFVIV TEEAIAKGIR RIVAVTGAEA QKALRKAESL KKCLSVMEAK
     VKAQTAPNKD VQREIADLGE ALATAVIPQW QKDELRETLK SLKKVMDDLD RASKADVQKR
     VLEKTKQFID SNPNQPLVIL EMESGASAKA LNEALKLFKM HSPQTSAMLF TVDNEAGKIT
     CLCQVPQNAA NRGLKASEWV QQVSGLMDGK GGGKDVSAQA TGKNVGCLQE ALQLATSFAQ
     LRLGDVKN
//
